NCT00575666View on ClinicalTrials.gov

Intranasal Insulin Treatment in Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Schizophrenia
Interventions
DRUG

Insulin or Placebo

intranasal, 40IU, 4 times daily

Trial Locations (1)

01605

University of Massachusetts Medical School, Worcester

All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Massachusetts, Worcester

OTHER

NCT00575666 - Intranasal Insulin Treatment in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter